Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Breast cancer, Secondary cancers
Closed
Phase 2
This study is looking at alpelisib with either fulvestrant or letrozole for advanced breast cancer that has continued to grow.
It is for men and women whose breast cancer has spread into surrounding tissue (is locally advanced) or elsewhere in the body. And whose breast cancer cells have:
receptors for oestrogen or progesterone (is hormone receptor positive)
low or no amounts of (this is called HER2 negative breast cancer)
a change to the PIK3CA gene
Recruitment start: 1 January 2018
Recruitment end: 30 September 2020
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Nick Turner
Novartis
Last reviewed: 29 September 2020
CRUK internal database number: 15219
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
